Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > ORGANIZATION
ORGANIZATION
- Japanese Pharma CEOs Gearing Up for New Endeavors in 2020, Fret Scope of Off-Year Re-Pricing
January 9, 2020
- As Off-Year Re-Pricing Looms, JPMA Chief Prods Govt to Minimize Product Coverage
January 7, 2020
- Generic Use Rate at 76.9% in July-September: JGA
December 27, 2019
- Boehringer’s Thorsten Poehl Named as New EFPIA Japan Chief
December 24, 2019
- Industry Leaders Issue Statements on FY2020 Reform Package; Improved PMP Criteria Given Certain Credit
December 23, 2019
- With PMD Law Amended, Japan Pharma Industry Revs Up Work for Electronic Distribution of Prescribing Info
December 5, 2019
- Generic Association to Present Policy Proposal for Govt’s 2020 Honebuto Policy
November 20, 2019
- RIKEN Develops Supercomputer for Molecular Dynamics Simulation, Will Be Made Available to Drug Makers for Drug Discovery Use
November 19, 2019
- JPWA Compares Traceability Regulations to Prevent Distribution of Counterfeit Drugs in Japan, US, EU
November 13, 2019
- JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
October 18, 2019
- Obituary: Harrison Cook, Eli Lilly
October 15, 2019
- Japan Pharmacist Group Taps Ex-Bureaucrat Isobe for Director Post
October 11, 2019
- Patients Want Access to Innovative Drugs Even If Expensive: PhRMA Survey
October 7, 2019
- PhRMA Chair Urges Japan to Rectify PMP Criteria, Narrow Definition of Innovation
October 4, 2019
- Japan Doctors’ Group to Issue Statement to Push for HPV Vaccines by FY2019-End
October 3, 2019
- Generic Industry Pondering Specific Proposal to Address Unreasonable Price Rises
October 2, 2019
- Generic Association Focuses on Pre-symptomatic/Preventive Care and Overseas Expansion in “Post-80% Era”
October 2, 2019
- Generic Use Rate at 75.8% in April-June: JGA
September 27, 2019
- Janssen’s Chris Hourigan Succeeds Jonsson as PhRMA Japan Chair
September 26, 2019
- EFPIA Japan Stresses Safety First and Need for Doctors’ Support on Delisting of OTC-Like Drugs, Notes Good Examples Overseas
September 25, 2019
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…